EPIGENETIC THERAPIES AS MOLECULAR PROBES TO INVESTIGATE THE MOLECULAR PATHOGENESIS OF LEUKAEMIA

Grant number: 1106444 | Funding period: 2016 - 2020

Completed

Abstract

A major limitation to the success of targeted therapies in cancer is the fact that we have few if any tools to study in detail their mechanism of action within cancerous and normal cells. If we were able to visualise these drugs within cells and precisely characterise the proteins, DNA and RNA within a cell that interact with these therapies we will be able to identify strategies that can optimise their efficacy and reduce the side-effects of these treatments.

Related publications (6)

Researchers